Viscum Album L. Extracts in Breast and Gynaecological Cancers: a Systematic Review of Clinical and Preclinical Research

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2009 Jun 13

PMID 19519890

Citations 53

Authors

Gunver S Kienle

Anja Glockmann

Michael Schink

Helmut Kiene

Affiliations

Soon will be listed here.

Abstract

Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal plant extract in gynaecological and breast-cancer treatment.

Methods: Systematic review to evaluate clinical studies and preclinical research on the therapeutic effectiveness and biological effects of VAE on gynaecological and breast cancer. Search of databases, reference lists and expert consultations. Criteria-based assessment of methodological study quality.

Results: 19 randomized (RCT), 16 non-randomized (non-RCT) controlled studies, and 11 single-arm cohort studies were identified that investigated VAE treatment of breast or gynaecological cancer. They included 2420, 6399 and 1130 patients respectively. 8 RCTs and 8 non-RCTs were embedded in the same large epidemiological cohort study. 9 RCTs and 13 non-RCTs assessed survival; 12 reported a statistically significant benefit, the others either a trend or no difference. 3 RCTs and 6 non-RCTs assessed tumour behaviour (remission or time to relapse); 3 reported statistically significant benefit, the others either a trend, no difference or mixed results. Quality of life (QoL) and tolerability of chemotherapy, radiotherapy or surgery was assessed in 15 RCTs and 9 non-RCTs. 21 reported a statistically significant positive result, the others either a trend, no difference, or mixed results. Methodological quality of the studies differed substantially; some had major limitations, especially RCTs on survival and tumour behaviour had very small sample sizes. Some recent studies, however, especially on QoL were reasonably well conducted. Single-arm cohort studies investigated tumour behaviour, QoL, pharmacokinetics and safety of VAE. Tumour remission was observed after high dosage and local application. VAE application was well tolerated. 34 animal experiments investigated VAE and isolated or recombinant compounds in various breast and gynaecological cancer models in mice and rats. VAE showed increase of survival and tumour remission especially in mice, while application in rats as well as application of VAE compounds had mixed results. In vitro VAE and its compounds have strong cytotoxic effects on cancer cells.

Conclusion: VAE shows some positive effects in breast and gynaecological cancer. More research into clinical efficacy is warranted.

Citing Articles

Clinical characteristics and therapeutic behavior of breast cancer patients using mistletoe therapy consulting a clinic offering integrative oncology: a registry data analysis.

Kruerke D, Schenker M, Matter-Walstra K BMC Complement Med Ther. 2023; 23(1):395.

PMID: 37924102 PMC: 10623842. DOI: 10.1186/s12906-023-04219-x.

The Anti-Inflammatory Activity of .

Nicoletti M Plants (Basel). 2023; 12(7).

PMID: 37050086 PMC: 10096603. DOI: 10.3390/plants12071460.

Systematic analysis of mistletoe prescriptions in clinical studies.

Staupe H, Buentzel J, Keinki C, Buentzel J, Huebner J J Cancer Res Clin Oncol. 2022; 149(9):5559-5571.

PMID: 36481925 PMC: 10356894. DOI: 10.1007/s00432-022-04511-2.

Additional treatment with mistletoe extracts for patients with breast cancer compared to conventional cancer therapy alone - efficacy and safety, costs and cost-effectiveness, patients and social aspects, and ethical assessment.

Schnell-Inderst P, Steigenberger C, Mertz M, Otto I, Flatscher-Thoni M, Siebert U Ger Med Sci. 2022; 20:Doc10.

PMID: 36160875 PMC: 9487779. DOI: 10.3205/000312.

Interactions Between Natural Products and Tamoxifen in Breast Cancer: A Comprehensive Literature Review.

Yen C, Zhao F, Yu Z, Zhu X, Li C Front Pharmacol. 2022; 13:847113.

PMID: 35721162 PMC: 9201062. DOI: 10.3389/fphar.2022.847113.

References

Ziegler R, Grossarth-Maticek R . Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador). Evid Based Complement Alternat Med. 2008; 7(2):157-66. PMC: 2862937. DOI: 10.1093/ecam/nen025. View

Schoffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A . Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer. 2005; 41(10):1431-8. DOI: 10.1016/j.ejca.2005.03.019. View

. Stat bite: Number of cancer survivors by site, 2003. J Natl Cancer Inst. 2006; 98(21):1514. DOI: 10.1093/jnci/djj435. View

Ulrich W, MECHELKE F . [Reactions of in vitro cultures of human fibroblasts, of HeLa-cells and of murine L-cells on application of a drug from Viscum album L. (author's transl)]. Arzneimittelforschung. 1980; 30(10):1722-5. View

Jager S, Winkler K, Pfuller U, Scheffler A . Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med. 2007; 73(2):157-62. DOI: 10.1055/s-2007-967106. View

Kienle G, Kiene H . Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007; 12(3):103-19. View

Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S . An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm. 2001; 16(1):55-62. DOI: 10.1089/108497801750096041. View

Gabius H, Darro F, Remmelink M, Andre S, Kopitz J, Danguy A . Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest. 2001; 19(2):114-26. DOI: 10.1081/cnv-100000146. View

Grossarth-Maticek R, Ziegler R . Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res. 2006; 11(11):485-95. View

10.

Bantel H, Engels I, Voelter W, Schulze-Osthoff K, Wesselborg S . Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res. 1999; 59(9):2083-90. View

11.

Valentiner U, Pfuller U, Baum C, Schumacher U . The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology. 2002; 171(2-3):187-99. DOI: 10.1016/s0300-483x(01)00581-9. View

12.

KLAMERTH O, VESTER F, Kellner G . Inhibitory effects of a protein complex from Viscum album on fibroblasts and HeLa cells. Hoppe Seylers Z Physiol Chem. 1968; 349(6):863-4. View

13.

Berger M, Schmahl D . Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. J Cancer Res Clin Oncol. 1983; 105(3):262-5. DOI: 10.1007/BF00395755. View

14.

Helyer L, Chin S, Chui B, Fitzgerald B, Verma S, Rakovitch E . The use of complementary and alternative medicines among patients with locally advanced breast cancer--a descriptive study. BMC Cancer. 2006; 6:39. PMC: 1475605. DOI: 10.1186/1471-2407-6-39. View

15.

Harmsma M, Gromme M, Ummelen M, Dignef W, Tusenius K, Ramaekers F . Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. Int J Oncol. 2004; 25(6):1521-9. View

16.

Klett C, Anderer F . Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract. Arzneimittelforschung. 1989; 39(12):1580-5. View

17.

Bock P, Friedel W, Hanisch J, Karasmann M, Schneider B . [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results...]. Arzneimittelforschung. 2004; 54(8):456-66. DOI: 10.1055/s-0031-1296999. View

18.

Jurin M, Zarkovic N, Hrzenjak M, Ilic Z . Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology. 1993; 50(6):393-8. DOI: 10.1159/000227217. View

19.

Deliorman Orhan D, Kupeli E, Yesilada E, Ergun F . Anti-inflammatory and antinociceptive activity of flavonoids isolated from Viscum album ssp. album. Z Naturforsch C J Biosci. 2006; 61(1-2):26-30. DOI: 10.1515/znc-2006-1-205. View

20.

Burger A, Mengs U, Kelter G, Schuler J, Fiebig H . No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res. 2003; 23(5A):3801-6. View